Search Resources (English): Women and Health Protection (WHP)

Results 41 - 50 of 63

Results

Health concerns for Diane-35: drug advertised widely to teens and doctors in Canada despite health warnings  
http://www.cwhn.ca/node/39511
Discusses the health concerns for Diane-35, a combination product advertised as a birth control pill and acne medication. Looks at how this drug is advertised to both physicians and consumers. (See Details)
Published: 2004
Evra and the environment  
http://www.whp-apsf.ca/en/documents/evra.html
Explains, by using the Evra patch as an example, how the drug approval process does not take drug disposal into account. Lists ways to prevent unused or expired medications from entering the ecosystem. (See Details)
Published: 2004
Illegal direct-to-consumer prescription drug advertising in Canada, 1999 to 2001: when drug companies skirt the law and the gove
Follows a campaign and complaint process regarding direct-to-consumer advertising of prescription drugs.
Published: 2002
SSRI antidepressants: their place in women's lives  
http://www.whp-apsf.ca/en/documents/ssri.html
Explores SSRI use in women and its effects. Also looks at alternatives to SSRIs. (See Details)
Published: 2005
Pharmaceuticals in our water: a new threat to public health?  
http://www.whp-apsf.ca/en/documents/pharmWater.html
Summarizes what is known about pharmaceutical and personal care products and their impact on water pollution. Describes what can be done to reverse the threat these products pose to the population's health and to the environment. (See Details)
Published: 2004
How safe are our medicines? Monitoring the risks of drugs after they are approved for marketing  
http://www.whp-apsf.ca/en/documents/how_safe.html
Discusses the drug approval process in Canada, post-approval drug surveillance, adverse drug reactions, and notification of those at risk of harm. Recommends measures to ensure drug safety for Canadian women and their families. (See Details)
Published: 2000
Transparency and the drug approval process at Health Canada  
http://www.whp-apsf.ca/en/documents/transparency.html
Argues that the federal government is protecting drug companies instead of the public by keeping information about the drug approval process secret. Examines the impact of this on women's health. (See Details)
Published: 2005
Reflections on Depo Provera: Contributions to Improving Drug Regulation in Canada  
http://www.whp-apsf.ca/pdf/reflectionsOnDepoProvera.pdf

Examines the ongoing story of Depo Provera, including: its regulatory history; how it has been and continues to be used, and; what is known about its safety profile.

 (See Details)
Published: October 2007
Drugs, devices and women's health: advocating for protection   
http://www.acewh.dal.ca/pdf/Looking%20Back%20presentations/Rochon%20Ford%20-%20Drugs,%20Devices%20and%20Women%27s%20Health.pdf

Powerpoint presentation on some of the work of Women and Health Protection, including research into the effects of Direct-to-Consumer Advertising (DTCA) of prescrption drugs, the CanWest Charter Challenge, a public forum on silicone gel breast implants, and women and statins.

 (See Details)
Published: March 2009
Evidence for caution: What women need to know about statins  
http://www.whp-apsf.ca/pdf/Evidence%20for%20Caution%20-%20Facts%20to%20Act%20On.pdf

Based on Evidence for Caution:  Women and Statin Use (2007) by Harriet Rosenberg and Danielle Allard.

 (See Details)
Published: 2009